Product Information
Registration Status: ActiveSIN03471P
AMINOPHYLLINE INJECTION 0.25g/10ml is approved to be sold in Singapore with effective from 1989-06-21. It is marketed by ATLANTIC PHARMACEUTICAL (S) PTE LTD, with the registration number of SIN03471P.
This product contains Aminophylline 0.25g/10ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by ATLANTIC LABORATORIES CORPN LTD in THAILAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.
Indication
For the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
Mechanism of Action
Aminophylline is the ethylenediamine salt of theophylline. After ingestion, theophylline is released from aminophylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
Clearance
* 0.29 mL/kg/min [postnatal age 3-15 days] * 0.64 mL/kg/min [postnatal age 25-57 days] * 1.7 mL/kg/min [ 1-4 years] * 1.6 mL/kg/min [4-12 years] * 0.9 mL/kg/min [13-15 years] * 1.4 mL/kg/min [16-17 years] * 0.65 mL/kg/min [Adults (16-60 years), non-smoking asthmatics] * 0.41 mL/kg/min [Elderly (>60 years). liver, and renal function] * 0.33 mL/kg/min [Acute pulmonary edema] * 0.54 mL/kg/min [COPD->60 years, stable non-smoker >1 year] * 0.48 mL/kg/min [COPD with cor pulmonale] * 1.25 mL/kg/min [Cystic fibrosis (14-28 years)] * 0.31 mL/kg/min [Liver disease -cholestasis] * 0.35 mL/kg/min [cirrhosis] * 0.65 mL/kg/min [acute hepatitis] * 0.47 mL/kg/min [Sepsis with multi-organ failure] * 0.38 mL/kg/min [hypothyroid] * 0.8 mL/kg/min [hyperthyroid]
Active Ingredient/Synonyms
Aminophyllin | Somophyllin | Theophylline ethylenediamine | Aminophylline |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.